“MD Anderson is a leader in clinical research for both hematological and solid tumor oncology, and we are excited to enter this broad collaboration,” said Allen Yang, M.D., Ph.D., senior vice president and chief medical officer at Xencor. “This alliance partnership will enable us to expand our ongoing efforts into additional indications, generate new clinical insights, inform key decisions and accelerate development timelines across our oncology portfolio. We look forward to working closely with MD Anderson as we advance new therapies to patients in need.”
Xencor’s clinical-stage bispecific antibodies and cytokines are engineered with a heterodimer Fc domain (antibody tail), which enables their rapid design, simplified development and stable structure. Nine XmAb bispecific antibodies and one engineered cytokine are being evaluated in Phase 1 clinical studies conducted by Xencor and its partners:
- CD3 bispecific antibodies contain a tumor associated antigen (TAA) binding domain and a second binding domain targeted to CD3, an activating receptor on T cells, with the goal to recruit or activate T cells against tumors with the antigen target. Xencor’s CD3 bispecific candidates in Phase 1 development include vibecotamab (CD123 x CD3) for patients with acute myeloid leukemia, plamotamab (CD20 x CD3) for patients with B cell malignancies and tidutamab (SSTR2 x CD3) for patients with neuroendocrine tumors and gastrointestinal stromal tumors.
- Tumor microenvironment (TME) activator bispecific antibodies promote tumor-selective T-cell activation by targeting multiple checkpoints or co-stimulating receptors. TME bispecifics incorporate Xencor’s Xtend™ technology for longer half-life. XmAb20717 (PD1 x CTLA4), XmAb22841 (CTLA4 x LAG3) and XmAb23104 (PD1 x ICOS) are being evaluated in Phase 1 studies in patients with select advanced solid tumors.
- Cytokines built with Xencor’s XmAb bispecific Fc domain have their potencies tuned to improve therapeutic index and also incorporate Xtend technology for longer half-life. Xencor and its co-development partner Genentech are evaluating XmAb24306, a novel IL15 cytokine-Fc fusion protein, in a Phase 1 study in patients with solid tumors.
“Xencor’s portfolio of novel antibody-based therapies offers a unique opportunity to evaluate a variety of clinical hypotheses for improved cancer treatments,” said Christopher Flowers, M.D., ad interim division head of Cancer Medicine at MD Anderson. “By working collaboratively, we aim to identify potential benefits for many patients with hematologic cancers and solid tumors.”
– 30 –
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Currently, 18 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
About MD Anderson The University of Texas MD Anderson Cancer Center in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution’s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 51 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is ranked No.1 for cancer care in U.S. News & World Report’s “Best Hospitals” survey. It has ranked as one of the nation’s top two hospitals for cancer care since the survey began in 1990, and has ranked first 16 times in the last 19 years. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).